Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Лечение менопаузальных расстройств при наличии риска гиперплазии эндометрия у женщин с избыточной массой тела
Лечение менопаузальных расстройств при наличии риска гиперплазии эндометрия у женщин с избыточной массой тела
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Серов В.Н. Гинекологическая эндокринология. 1998; 358.
2. Blumel JL, Cruz MN, Aparicio NJ. Menopausal travsition, physiopathology, clinical and treatment. Medicina (B – Aries) 2002; 62 (1): 57–65.
3. Mattews D, Hosker J, Rudenski A et al. Homeostasis model asessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412–9.
4. Clinician`s Manual on Total Risk Management. A guide to prevention of Coronary Heart Disease. Science Press Ltd and Society of Cardiology, 2000.
5. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SRB-1 on lipoprotein metabolism and atherosclerosis. Arterioscler Tromb Vasc Biol 2003; 23: 1732–8.
6. Koh KK, Jin DK, Yang SH et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Crculation 2001; 103: 1961–6.
7. Gobsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentration: analysis of studies published from 1974–2000. Fertil Steril 2001; 75 (5): 898–915.
8. Jansen H, Verhoeven AJM, Sijbrands JG. Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Research 2002; 43: 1352–62.
9. Kwok S, Selby PL, McElduff P et al. Progestogens of varying androgenecity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol 2004; 61: 760–7.
10. Kalish MK, Barret-Connor E, Laughlin GA, Gulansky BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88 (4): 1646–52.
11. Rosano GMC, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in postmenopausal women: implications for cardioprotection. Maturitas 2003; 46 (S1): 17–29.
12. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпрессинформ, 2004.
13. Yasui T, Umino Y, Takikawa M et al. Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index. Menopause 2005; 12 (2): 223–31.
14. Rubig A. Drospirenone, a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6 (Suppl. 3): 49–54.
15. Григорян О.Р. Влияние препарата "Фемостон 1/5" на композиционный состав тела у женщин с сахарным диабетом 2 типа в период постменопаузы. Ожирен. и метабол. 2004; 2: 30–34.
16. Van de Weijer PHM, Scholten P, van de Mooren MJ et al. Bleeding patterns and histology during administration of low dose estradiol sequentially combined with dydrogesterone. Cimacteric 1999; 2: 1–9.
2. Blumel JL, Cruz MN, Aparicio NJ. Menopausal travsition, physiopathology, clinical and treatment. Medicina (B – Aries) 2002; 62 (1): 57–65.
3. Mattews D, Hosker J, Rudenski A et al. Homeostasis model asessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412–9.
4. Clinician`s Manual on Total Risk Management. A guide to prevention of Coronary Heart Disease. Science Press Ltd and Society of Cardiology, 2000.
5. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SRB-1 on lipoprotein metabolism and atherosclerosis. Arterioscler Tromb Vasc Biol 2003; 23: 1732–8.
6. Koh KK, Jin DK, Yang SH et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Crculation 2001; 103: 1961–6.
7. Gobsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentration: analysis of studies published from 1974–2000. Fertil Steril 2001; 75 (5): 898–915.
8. Jansen H, Verhoeven AJM, Sijbrands JG. Hepatic lipase: a pro- or anti-atherogenic protein? J Lipid Research 2002; 43: 1352–62.
9. Kwok S, Selby PL, McElduff P et al. Progestogens of varying androgenecity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol 2004; 61: 760–7.
10. Kalish MK, Barret-Connor E, Laughlin GA, Gulansky BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the postmenopausal estrogen/progestin intervention trial. J Clin Endocrinol Metab 2003; 88 (4): 1646–52.
11. Rosano GMC, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in postmenopausal women: implications for cardioprotection. Maturitas 2003; 46 (S1): 17–29.
12. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. М.: МЕДпрессинформ, 2004.
13. Yasui T, Umino Y, Takikawa M et al. Effects of postmenopausal hormone therapy every day and every other day on lipid levels according to difference in body mass index. Menopause 2005; 12 (2): 223–31.
14. Rubig A. Drospirenone, a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003; 6 (Suppl. 3): 49–54.
15. Григорян О.Р. Влияние препарата "Фемостон 1/5" на композиционный состав тела у женщин с сахарным диабетом 2 типа в период постменопаузы. Ожирен. и метабол. 2004; 2: 30–34.
16. Van de Weijer PHM, Scholten P, van de Mooren MJ et al. Bleeding patterns and histology during administration of low dose estradiol sequentially combined with dydrogesterone. Cimacteric 1999; 2: 1–9.
Авторы
И.В.Кузнецова, М.В.Якокутова
Кафедра акушерства и гинекологии РМАПО (зав. кафедрой – профессор Н.М.Подзолкова)
Кафедра акушерства и гинекологии РМАПО (зав. кафедрой – профессор Н.М.Подзолкова)
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.